Inventor · disambiguated record
Andrew J. Phillips
Also filed as: PHILLIPS ANDREW · PHILLIPS ANDREW J · PHILLIPS ANDREW JOHN
28 granted patents·8 pending applications·253 citations·filing 2011–2024
96Inventor score
Files withC4 THERAPEUTICS INC22DANA FARBER CANCER INST INC6RONSHEIM MELANIE SIMONE3ACERTA PHARMA BV2FOREST LABORATORIES HOLDINGS LTD1
Top patents by PatentIndex Score
36 records- 0197US11407732B1Tricyclic degraders of Ikaros and AiolosC4 THERAPEUTICS INC·Filed 2021·Granted Aug 9, 2022·10 cites·30 claims
- 0297US11185592B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·20 cites·26 claims
- 0397US10660968B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·32 cites·35 claims
- 0496US11524949B2Degraders and Degrons for targeted protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Dec 13, 2022·7 cites·18 claims
- 0596US10905768B1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Feb 2, 2021·31 cites·20 claims
- 0696US10849982B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted Dec 1, 2020·43 cites·17 claims
- 0796US10646575B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 12, 2020·32 cites·28 claims
- 0895US12048747B2Substituted piperidine Degronimers for Target Protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Jul 30, 2024·4 cites·22 claims
- 0994US11459335B2N/O-linked Degrons and Degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·8 cites·23 claims
- 1093US11992531B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted May 28, 2024·3 cites·31 claims
- 1191US11311609B2Regulating chimeric antigen receptorsDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 26, 2022·6 cites·29 claims
- 1291US9284314B2Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereofRONSHEIM MELANIE SIMONE·Filed 2015·Granted Mar 15, 2016·15 cites·15 claims
- 1391US8829191B2Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereofRONSHEIM MELANIE SIMONE·Filed 2012·Granted Sep 9, 2014·18 cites·7 claims
- 1490US12048748B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Jul 30, 2024·1 cites·21 claims
- 1590US8969566B2Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereofRONSHEIM MELANIE SIMONE·Filed 2014·Granted Mar 3, 2015·17 cites·9 claims
- 1687US12180225B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Dec 31, 2024·1 cites·19 claims
- 1786US11046954B2Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responsesDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 29, 2021·2 cites·17 claims
- 1885US12076405B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Sep 3, 2024·1 cites·20 claims
- 1983US2025057957A1Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2083US2025121069A1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2181US11753397B2Cereblon binders for the degradation of ikarosC4 THERAPEUTICS INC·Filed 2020·Granted Sep 12, 2023·1 cites·19 claims
- 2280US2025127903A1Substituted piperidine degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2376US12441740B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·0 cites·19 claims
- 2474US2022135967A1Tunable endogenous protein degradationDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 2572US12448387B2Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamideACERTA PHARMA BV·Filed 2024·Granted Oct 21, 2025·0 cites·31 claims
- 2671US2021301286A1Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responsesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2770US12024520B2Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamideACERTA PHARMA BV·Filed 2019·Granted Jul 2, 2024·1 cites·29 claims
- 2868US11293023B2Tunable endogenous protein degradationDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 5, 2022·0 cites·13 claims
- 2967US2023082430A1Tricyclic degraders of ikaros and aiolosC4 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3062US2023190760A1Advantageous therapies for disorders mediated by ikaros or aiolosC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3162US2019076539A1Amine-linked c3-glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3261US12454521B2Targeted protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Oct 28, 2025·0 cites·25 claims
- 3355US9422340B2Macrocyclic compounds useful as inhibitors of histone deacetylasesUNIV COLORADO REGENTS·Filed 2014·Granted Aug 23, 2016·0 cites·15 claims
- 3450US9695122B2Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereofFOREST LABORATORIES HOLDINGS LTD·Filed 2016·Granted Jul 4, 2017·0 cites·14 claims
- 3548US12023385B2Tunable endogenous protein degradation with heterobifunctional compoundsDANA FARBER CANCER INST INC·Filed 2018·Granted Jul 2, 2024·0 cites·24 claims
- 3641US8754050B2Macrocyclic compounds useful as inhibitors of histone deacetylasesLIU XUEDONG·Filed 2011·Granted Jun 17, 2014·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Andrew J. Phillips files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →